Condition: Kidney Cancer · Kidney Neoplasms · Kidney Diseases · Sponsor: University Hospital, Ghent
A proposed new tool ('DIPLANN-tool' - Digital Planning in Nephrectomy) for predicting kidney perfusion zones on a segmented 3D model during robot-assisted partial nephrectomy (RAPN) for localized renal cancer demonstrated high accuracy when planning selective clamping (SC) for RAPN. However, the tool's clinical added value still needs to be confirmed. Therefore, a randomized controlled trial using a study and control group is the preferred study design. Experimental group: the use of the DIPLANN-tool + conventional computed tomography (CT) imaging for preoperative planning and perioperative guidance during RAPN. Control group: the use of only conventional CT imaging for preoperative planning and perioperative guidance during RAPN (= current standard of care). The primary endpoint is planning and performing as planned a SC strategy. Secondary endpoints include patients' health, patients' insight and surgeons' benefits.
This description comes directly from the study's public registry record.
Joris Vangeneugden, MD · +32 9 332 22 76 · joris.vangeneugden@ugent.be
Charles Van Praet, MD, PhD · +32 9 332 22 76 · charles.vanpraet@uzgent.be
Always discuss trial participation with your own doctor first.
| AZORG | Aalst, Belgium | Recruiting |
| AZ Sint-Jan | Bruges, Belgium | Recruiting |
| ZOL | Genk, Belgium | Recruiting |
| AZ Maria Middelares | Ghent, Belgium | Recruiting |
| Ghent University Hospital | Ghent, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06536439